InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Findings Set Stage for Future Cannabinoid Compound Studies
- Fundamental value drivers of InMed Pharmaceuticals are its drug development pipeline and proprietary biosynthesis technology in cannabinoid manufacturing
- Biopharmaceutical company already has two drug candidates – INM-085 and INM-750 – in the multi-billion dollar ocular and dermatology markets
- INM-085 and INM-750 target markets valued in excess of $5 billion and $1 billion, respectively
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed. It may eventually lead to a product which encompasses cannabinoid compounds targeting pain-related receptors in the body.
InMed is a Vancouver-based preclinical stage biopharmaceutical company specializing in the development of cannabinoid-based therapies using novel drug therapies and delivery systems. Value drivers for the company are its proprietary process for cannabinoid manufacturing and its drug candidate pipeline. It already has two preclinical product candidates. INM-085 has been developed for the treatment of glaucoma, an eye disease that accounts for a greater than $5 billion global market. The other is INM-750 for the treatment of orphan disease epidermolysis bullosa (EB), which is characterized by fragile skin. There are no approved therapies for the disease in this $1 billion market.
The InMed Pharmaceuticals article in the Journal (http://nnw.fm/3o95X) focuses on how THC impacts the peripheral cannabinoid (CB) receptors CB1 and CB2. The results are that THC activates the CB1 receptor to provide analgesic relief without side effects. The study results suggest that THC could provide a novel approach to offer that relief through the peripheral application of cannabinoids.
The article is titled, “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation.” The study was co-funded by Canadian non-profit organization Mitacs and InMed Pharmaceuticals. In a news release, Hossain, co-author of the findings report, said, “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
The result could be a valuable approach in the cannabinoid treatment of severe pain. The model used in this study mimics the muscle pain of temporomandibular joint disorders (TMD) that affect the jaw muscle. TMD is a chronic pain condition that’s difficult to treat.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Fundamental value drivers of InMed Pharmaceuticals are its drug development pipeline and proprietary biosynthesis technology in cannabinoid manufacturing
- Biopharmaceutical company already has two drug candidates – INM-085 and INM-750 – in the multi-billion dollar ocular and dermatology markets
- INM-085 and INM-750 target markets valued in excess of $5 billion and $1 billion, respectively
InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) study, which generated an article published in the European Journal of Pain (http://nnw.fm/SVF1j), sets the stage for more research into how a topically-applied drug can provide relief of chronic or acute pain without central side effects, according to Dr. Sazzad Hossain, chief scientific officer of InMed. It may eventually lead to a product which encompasses cannabinoid compounds targeting pain-related receptors in the body.
InMed is a Vancouver-based preclinical stage biopharmaceutical company specializing in the development of cannabinoid-based therapies using novel drug therapies and delivery systems. Value drivers for the company are its proprietary process for cannabinoid manufacturing and its drug candidate pipeline. It already has two preclinical product candidates. INM-085 has been developed for the treatment of glaucoma, an eye disease that accounts for a greater than $5 billion global market. The other is INM-750 for the treatment of orphan disease epidermolysis bullosa (EB), which is characterized by fragile skin. There are no approved therapies for the disease in this $1 billion market.
The InMed Pharmaceuticals article in the Journal (http://nnw.fm/3o95X) focuses on how THC impacts the peripheral cannabinoid (CB) receptors CB1 and CB2. The results are that THC activates the CB1 receptor to provide analgesic relief without side effects. The study results suggest that THC could provide a novel approach to offer that relief through the peripheral application of cannabinoids.
The article is titled, “Delta-9-tetrahydrocannabinol decreases masticatory muscle sensitization in female rats through peripheral cannabinoid receptor activation.” The study was co-funded by Canadian non-profit organization Mitacs and InMed Pharmaceuticals. In a news release, Hossain, co-author of the findings report, said, “This study sets the stage for advanced work in various pain models to explore the role of several cannabinoid compounds, applied as topical agents, to target the CB1 and other pain-related receptors.”
The result could be a valuable approach in the cannabinoid treatment of severe pain. The model used in this study mimics the muscle pain of temporomandibular joint disorders (TMD) that affect the jaw muscle. TMD is a chronic pain condition that’s difficult to treat.
For more information, visit the company’s website at www.InMedPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
